Aripiprazole Tablets Recalled Following FDA Inspection for Manufacturing Deviations
Accord Healthcare recalls 539,004 bottles of Aripiprazole 10 mg tablets distributed in the US, Puerto Rico, and Canada due to manufacturing process deviations found during an FDA inspection.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. CGMP deviations represent manufacturing process compliance issues without an identified specific product hazard. The recall appears precautionary.
Plain-English summary
Accord Healthcare, Inc. is recalling Aripiprazole Tablets, USP 10 mg, packaged in 30-count and 100-count bottles, due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA facility inspection. The recalled product was distributed throughout the United States, Puerto Rico, and Canada.
The recall affects 539,004 bottles manufactured by Intas Pharmaceuticals Limited in India and distributed by Accord Healthcare. Affected batches include P2006421, P2004882, P2004939, P2004883, P2004940, P2004942, P2004943, P2004944 (expiring 8/31/2023); P2107593, P2106907, P2106906, P2106908, P2106909 (expiring 10/31/2024); P2102144 (expiring 3/31/2023); P2106903 (expiring 10/31/2023); and P2204437 (expiring 7/31/2025).
Patients taking this medication should contact their healthcare provider to discuss whether they have a recalled batch and determine appropriate next steps. Do not stop taking the medication without medical guidance, as abruptly discontinuing an antipsychotic can cause adverse health effects. Consumers may also report any side effects to the FDA through MedWatch.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Antipsychotic Medication
- Hazard
- manufacturing-process-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a)P2006421
- P2004882
- P2004939
- P2004883
- P2004940
- P2004942
- P2004943
- P2004944
- Exp. Date 8/31/2023
- P2107593
- P2106907
- P2106906
- P2106908
- P2106909
- Exp. Date 10/31/2024
- b)P2102144
- Exp. Date 3/31/2023
- P2106903 Exp. Date 10/31/2023
- P2204437
- Exp. Date 7/31/2025
UPCs (2)
- 316729280105
- 316729280013
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ARIPIPRAZOLE
- HighAripiprazole tablets recalled nationwide due to excess active ingredient
FDA (Drugs) · 2025-09-24
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- ModeratePrescription drug aripiprazole tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27